Keranova, a Saint-Etienne, France-based company that develops instruments for ophthalmic surgery, raised a Series A funding of €4m ($4.55m).
The round was led by Mérieux Développement and CEA Investissement with additional support from French public investment bank Bpifrance, which contributed €1m ($1.14m).
The company intends to use the funds for the development of prototype surgical equipment and the preclinical study; a regulatory prerequisite for filing for approval of the clinical trial.
Founded in 2015 by Fabrice Romano, CEO, who was joined by Sophie Valla, managing director and former EMEA business development manager pharmaceutical/surgical with Bausch and Lomb / Valeant, Keranova has developed a new surgical instrument that leverages the results of joint research by two multidisciplinary teams at Saint-Etienne’s Jean Monnet University and allows for a substantial reduction in manual intervention in favor of automation and precision. This will generate reproducibility and reduction of clinical risk (operator-dependent risk).